当代诊断性放射性示踪剂在乳腺癌管理中的应用现状:迈向诊疗一体化的第一步
本文为叙述性综述,聚焦当代PET放射性示踪剂在乳腺癌中的分子成像作用,概述针对程序性死亡配体1、人表皮生长因子受体2、聚腺苷二磷酸核糖聚合酶和雌激素受体等治疗靶点的诊断性示踪剂,并讨论治疗性放射性核素在乳腺癌管理中的进展。作者认为,用PET示踪剂对治疗靶点成像可能提供更可靠的精准医学工具,为合适的患者在合适的时间找到合适的治疗;除靶点可视化外,使用α或β发射同位素的诊疗一体化试验为转移性乳腺癌患者提供了未来的治疗选择。
要点
- 病理活检是靶向治疗生物标志物选择的当前参考标准,但存在瘤内与瘤间及空间异质性等局限。
- PET示踪剂可对PD-L1、HER2、PARP和雌激素受体等治疗靶点进行成像。
- α或β发射同位素的诊疗一体化试验为转移性乳腺癌提供未来治疗选择。
核心结论
- 用PET示踪剂对治疗靶点成像可能提供更可靠的精准医学工具,为合适的患者在合适的时间找到合适的治疗。
- 除治疗靶点可视化外,使用α或β发射同位素的诊疗一体化试验为转移性乳腺癌患者提供了未来的治疗选择。
研究设计与样本
- 本文为叙述性综述,聚焦当代放射性示踪剂PET分子成像在乳腺癌中的作用。
主要发现
- 概述了针对程序性死亡配体1、人表皮生长因子受体2、聚腺苷二磷酸核糖聚合酶和雌激素受体等治疗靶点的诊断性放射性示踪剂。
- 讨论了治疗性放射性核素在乳腺癌管理中的进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Expanding therapeutic possibilities have improved disease-related prospects for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference standard biomarker used to select for treatment with targeted anticancer drugs. This method has, however, several limitations, related to intra- and intertumoral as well as spatial heterogeneity in receptor expression as well as the need to perform invasive procedures that are not always technically feasible. MAIN BODY: In this narrative review, we focus on the current role of molecular imaging with contemporary radiotracers for positron emission tomography (PET) in breast cancer. We provide an overview of diagnostic radiotracers that represent treatment targets, such as programmed death ligand 1, human epidermal growth factor receptor 2, polyadenosine diphosphate-ribose polymerase and estrogen receptor, and discuss developments in therapeutic radionuclides for breast cancer management. CONCLUSION: Imaging of treatment targets with PET tracers may provide a more reliable precision medicine tool to find the right treatment for the right patient at the right time. In addition to visualization of the target of treatment, theranostic trials with alpha- or beta-emitting isotopes provide a future treatment option for patients with metastatic breast cancer.
引用
- Altena R, Tzortzakakis A, Af Burén S, et al. Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications. EJNMMI Res. 2023. PMID: 37195374. doi:10.1186/s13550-023-00995-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。